BJH - 2021, issue SPECIAL, january 2021
T. Tousseyn MD, PhD
The diagnosis of lymphomas requires multiple immunohistochemical (IHC) analyses in combination with additional tests, such as fluorescent in situ hybridization (FISH) and/or polymerase chain reaction (PCR) tests. During his lecture at the 2021 BHS general annual meeting, Dr. Thomas Touseyn discussed the contemporary role of the pathologist in the diagnostic work-up of aggressive lymphomas.
Read moreBJH - volume 11, issue Abstract Book BHS, february 2020
H. Maes MD, I. Geerts MD, M. Lefere , I. D'Hoore , P. Vermeylen , T. Tousseyn MD, PhD
BJH - volume 10, issue 6, october 2019
E. Van Valckenborgh PhD, M. Bakkus PhD, E. Boone PhD, A. Camboni MD, PhD, J-P. Defour PhD, B. Denys MD, H. Devos MD, L. Dewispelaere MD, G. Froyen PhD, A. Hébrant PhD, P. Heimann MD, PhD, P. Hermans MD, PhD, E. Heylen PhD, K. Jacobs PhD, F. Lambert MD, M. Le Mercier Apr, PhD, E. Lierman PhD, H. Louagie MD, PhD, B. Maes MD, PhD, M-B. Maes PhD, G. Martens MD, PhD, L. Michaux MD, PhD, F. Nollet PhD, MSc, H.A. Poirel MD, PhD, G. Raicevic PhD, P. Saussoy MD, PhD, T. Tousseyn MD, PhD, M. Van Den Bulcke PhD, P. Vandenberghe MD, PhD, K. Vandepoele PhD, P. Vannuffel PhD, T. Venken PhD, K. Vermeulen PhD
Molecular diagnostics have an increasing impact on diagnosis, risk stratification and targeted treatment in haemato-oncology. In the framework of a pilot study for the implementation of next-generation sequencing in the Belgian healthcare system, the Commission of Personalised Medicine was founded to give professional and evidence-based advice on the molecular analysis in haemato-oncology. This paper describes its recommendations for NGS analysis in myeloid malignancies. In addition, the minimally required set of genes that must be analysed is defined and algorithms for molecular workflow in myeloid malignancies are proposed.
(BELG J HEMATOL 2019;10(6):241–9)
Read moreBJH - volume 10, issue Abstract Book BHS, february 2019
J. Finalet Ferreiro , T. Tousseyn MD, PhD, O. Gheysens MD, PhD, G. Verhoef MD, PhD, M. André MD, PhD, P. Vandenberghe MD, PhD, L. Buedts PhD, L.M. Fornecker , J. Lazarovici , R. Casasnovas , C. Copie , L. Marcelis MD, PhD
BJH - volume 9, issue 3, june 2018
Y. Serroukh MD, PhD, H. Claerhout MD, A. Janssens MD, PhD, T. Tousseyn MD, PhD, N. Boeckx MD, PhD, J. Maertens MD, PhD, T. Devos MD, PhD
Aplastic anaemia is a rare condition characterised by pancytopenia and bone marrow hypocellularity and caused by the immune-mediated destruction of the haematopoietic precursors. The early complications are related to cytopaenias with infections being the major cause of morbi-mortality. The main long-term issue is clonal evolution to myelodysplastic syndrome or acute leukaemia. The diagnosis relies on exclusion of other causes of pancytopenia and characteristic pathologic findings. Severity is stratified according to peripheral blood counts. Nowadays, the survival of treated patients reaches 80–90%. The treatment of the severe form of aplastic anaemia consists on haematopoietic stem cell transplantation in eligible patients and immunosuppressive therapy in non-transplant candidates. Supportive therapy is an option in frail and/or elderly patients. Here, we define and briefly review the pathogenesis of aplastic anaemia. We propose a diagnostic and therapeutic strategy based on existing literature and experts’ recommendations. We finally report three cases illustrating particular clinical associations with pregnancy, hepatitis and paroxysmal nocturnal haemoglobinuria.
(BELG J HEMATOL 2018;9(3):76–85)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
S. van Aelst , H. Claerhout MD, C. Melis , T. Tousseyn MD, PhD, P. Vandenberghe MD, PhD, D. Dierickx MD, PhD, N. Boeckx MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
H. Maes MD, J. Maertens MD, PhD, S. Smits , E. Lierman PhD, N. Boeckx MD, PhD, T. Tousseyn MD, PhD, G. Verhoef MD, PhD, P. Vandenberghe MD, PhD
Top
